Peripheral T-cell lymphoma unspecified

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
6 Unique sponsors
11 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Corticosteroid 2 substances
HDAC inhibitor 1 substance
Antibody-drug conjugate (ADC) 1 substance
Alkylating agent 1 substance
Anthracycline 1 substance
Topoisomerase II inhibitor 1 substance
Vinca alkaloid 1 substance
Phase II/III: 1 Phase I/II: 1 Phase IV: 1 Phase I: 3 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase II/III

1 trial
  • Acrotech Biopharma Inc. Commercial
    BELINOSTAT; PRALATREXATE
    2023-507803-76-00 5 countries 2024 n=145 Orphan
    Recruiting

Phase I/II

1 trial
  • Fondazione Italiana Linfomi Ets Academic
    ROMIDEPSIN
    2024-511639-83-00 1 country 2014 n=125 Orphan
    Ended

Phase IV

1 trial
  • LYSARC Academic
    BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE MONOHYDRATE; DOXORUBICIN HYDROCHLORIDE; ETOPOSIDE; METHYLPREDNISOLONE HEMISUCCINATE; PREDNISONE; VINCRISTINE SULFATE
    2022-501710-62-02 2 countries 2023 n=204
    Recruiting

Phase I

3 trials
  • Kyowa Kirin Inc. Commercial
    IMP not specified
    2025-522523-96-00 2 countries n=34
    Pending
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-505813-26-00 5 countries 2024 n=48
    Ended

Phase I (First in Human)

1 trial
  • Taiho Oncology Inc. Commercial
    TOLINAPANT LACTATE
    2024-516679-33-00 2 countries 2017 n=16
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 2 Phase I 0
Kyowa Kirin Inc. Commercial 1 Phase I 0
Acrotech Biopharma Inc. Commercial 1 Phase II/III 1
Taiho Oncology Inc. Commercial 1 Phase I (First in Human) 0
LYSARC Academic 1 Phase IV 1
Fondazione Italiana Linfomi Ets Academic 1 Phase I/II 0
New trials by year
2023
1
2024
3
← All indication landscapes